Differences in Demographic, Clinical, and Symptom Characteristics and Quality of Life Outcomes Among Oncology XXXX with Different Types of @entity158 .

@entity1 @entity308 @entity101 @entity571 @entity5 @entity1295 @entity615 @entity148 @entity158 @entity25 @entity4740
UNASSIGNED: The purposes of this study, in oncology outpatients receiving chemotherapy ( @entity4740 , n=926), were to: describe the occurrence of different types of @entity158 (i.e., no @entity158 , only non- @entity5 (NCP), only @entity5 ( @entity5 ), or both @entity5 and NCP) and evaluate for differences in demographic, clinical, and symptom characteristics, and quality of life (QOL) among the four groups. @entity1 completed self-report questionnaires on demographic and symptom characteristics and QOL. @entity1 who had @entity158 were asked to indicate if it was or was not related to their @entity5 or its treatment. Medical records were reviewed for information on @entity5 and its treatments. In this study, 72.5% of the @entity1 reported @entity158 . Of the 671 who reported @entity158 , 21.5% reported only NCP, 37.0% only @entity5 , and 41.5% both @entity5 and NCP. Across the three @entity158 groups, worst @entity158 scores were in the moderate to severe range. Compared to the no @entity158 group, @entity1 with both @entity5 and NCP were significantly younger, more likely to be female, have a higher level of comorbidity and a poorer functional status. In addition, these @entity1 reported: higher levels of @entity308 , @entity148 , @entity1295 , and @entity25 ; lower levels of energy and attentional function; and poorer QOL. @entity1 with only NCP were significantly older than the other three groups. The most common comorbidities in the NCP group were @entity615 , @entity101 , @entity571 , and @entity308 . Unrelieved @entity5 and NCP continue to be significant problems. Oncology outpatients need to be assessed for both @entity5 and NCP conditions.
